Project description:we employed DNA microarray platform to compare the gene expression patterns in primary human cardiomyocytes treated with trastuzumab (50µg/ml), trastuzumab (50µg/ml) plus pertuzumab (50µg/ml), T-DM1 (10 µg/ml), or control (no treatment).
Project description:Microarray expression data from C57/Bl6Nand b1-adrenergic transgenic mice, including heart tissue, isolated cardiomycytes and fibroblast, and lung fibroblasts Expression data was further used to identify promising targets in cardiomyocytes that are also members of the ubiquitin proteasome system that are upregulated in heart cells
Project description:Background and Aims: It is known that inflammatory processes are activated in heart failure, but the regulation of cytokines and their role in the pathogenesis of the disease are not well understood. We have identified fractalkine as a possible novel mediator in HF development. To address this issue, we have performed microarray analysis of cardiomyocytes treated with different isoforms of fractalkine. Methods: Cardiomyocytes isolated from adult rat hearts and treated with different forms of fractalkine for 24 hours. Control cells were treated with BSA. Molecular alterations in myocardial tissue were measured by using cDNA microarrays. Molecular pathways affected were identified by the Ingenuity Pathway Analysis software. Results: Several molecular pathways were affected upon fractalkine stimulation of adult cardiomyocytes. Keywords: Fractalkines effect on cardiomyocytes
Project description:This SuperSeries is composed of the following subset Series: GSE29992: Genome-wide profiling of E12.5 cardiomyocytes RNA expression in both hetozygeous control and mutant GSE29994: ChIP-seq of Ezh2 and H3K27me3 in E12.5 heart apex Refer to individual Series
Project description:Dysregulation of miRs has been reported in a variety of cardiac diseases. In particular, it has reported that estrogen regulates a miRs network in female cardiac fibroblasts, thereby modulating a spectrum of genes involved in cardiac fibrosis and remodeling. However, the estrogen-responsive miRs in cardiomyocytes still remain to be elucidated. We used a microRNA microarray screening approach to address the miRs expression profiling in estrogen-treated cardiomyocytes.
